212 related articles for article (PubMed ID: 36401314)
1. Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition.
Guild A; Fritch J; Patel S; Reinhardt A; Acquazzino M
Pediatr Rheumatol Online J; 2022 Nov; 20(1):104. PubMed ID: 36401314
[TBL] [Abstract][Full Text] [Related]
2. Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.
Cheloff AZ; Al-Samkari H
Drugs Today (Barc); 2020 Jul; 56(7):439-446. PubMed ID: 32648854
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
Brossard P; Laveille C
Rheumatol Ther; 2024 Jun; 11(3):869-880. PubMed ID: 38662147
[TBL] [Abstract][Full Text] [Related]
4. Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis.
Garonzi C; Chinello M; Cesaro S
Expert Rev Clin Pharmacol; 2021 May; 14(5):527-534. PubMed ID: 33686916
[TBL] [Abstract][Full Text] [Related]
5. Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis.
Burn TN; Weaver L; Rood JE; Chu N; Bodansky A; Kreiger PA; Behrens EM
Arthritis Rheumatol; 2020 Feb; 72(2):335-347. PubMed ID: 31400073
[TBL] [Abstract][Full Text] [Related]
6. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
Irino K; Jinnouchi F; Nakano S; Sawabe T
Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281
[TBL] [Abstract][Full Text] [Related]
7. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.
Gloude NJ; Dandoy CE; Davies SM; Myers KC; Jordan MB; Marsh RA; Kumar A; Bleesing J; Teusink-Cross A; Jodele S
J Clin Immunol; 2020 Jul; 40(5):699-707. PubMed ID: 32447592
[TBL] [Abstract][Full Text] [Related]
8. Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with Chédiak-Higashi syndrome: a case report.
AlAhmari A; Khogeer H
J Med Case Rep; 2023 Mar; 17(1):113. PubMed ID: 36978158
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).
Merli P; Algeri M; Gaspari S; Locatelli F
Front Immunol; 2020; 11():608492. PubMed ID: 33424859
[TBL] [Abstract][Full Text] [Related]
10. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.
Vallurupalli M; Berliner N
Blood; 2019 Nov; 134(21):1783-1786. PubMed ID: 31537529
[TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Chandrakasan S; Jordan MB; Baker A; Behrens EM; Bhatla D; Chien M; Eckstein OS; Henry MM; Hermiston ML; Hinson AP; Leiding JW; Oladapo A; Patel SA; Pednekar P; Ray AK; Dávila Saldaña B; Sarangi SN; Walkovich KJ; Yee JD; Zoref-Lorenz A; Allen CE
Blood Adv; 2024 May; 8(9):2248-2258. PubMed ID: 38429096
[TBL] [Abstract][Full Text] [Related]
12. Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2.
Segal JE; Daley JD; Barnum JL; Salgado CM; Reyes-Mugica M; Schneider C; Gumus S; Thakrar D; Allen SW; Canna SW
J Clin Immunol; 2021 Jul; 41(5):987-991. PubMed ID: 33570715
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis and myelodysplastic syndrome: a case report and review of the literature.
Sun Y; Blieden C; Merritt BY; Sosa R; Rivero G
J Med Case Rep; 2021 Mar; 15(1):98. PubMed ID: 33648567
[TBL] [Abstract][Full Text] [Related]
15. Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Jordan MB; Locatelli F
Pediatr Blood Cancer; 2024 Feb; 71(2):e30778. PubMed ID: 38014905
[TBL] [Abstract][Full Text] [Related]
16. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
Jacqmin P; Laveille C; Snoeck E; Jordan MB; Locatelli F; Ballabio M; de Min C
Br J Clin Pharmacol; 2022 May; 88(5):2128-2139. PubMed ID: 34935183
[TBL] [Abstract][Full Text] [Related]
17. Emapalumab: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jan; 79(1):99-103. PubMed ID: 30623346
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus.
Keith MP; Pitchford C; Bernstein WB
J Clin Rheumatol; 2012 Apr; 18(3):134-7. PubMed ID: 22426581
[TBL] [Abstract][Full Text] [Related]
19. Mouse Cytomegalovirus Infection in BALB/c Mice Resembles Virus-Associated Secondary Hemophagocytic Lymphohistiocytosis and Shows a Pathogenesis Distinct from Primary Hemophagocytic Lymphohistiocytosis.
Brisse E; Imbrechts M; Put K; Avau A; Mitera T; Berghmans N; Rutgeerts O; Waer M; Ninivaggi M; Kelchtermans H; Boon L; Snoeck R; Wouters CH; Andrei G; Matthys P
J Immunol; 2016 Apr; 196(7):3124-34. PubMed ID: 26903481
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
Jianguo L; Zhixuan Z; Rong L; Xiaodong S
Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
